there's no money to be made from running a definitive diet or exercise trial.
a product such as bisantrene can ultimately be sold for big bucks if shown to help just a little bit.
who can make serious money out of recommending that women undergoing breast cancer treatment engage in an active exercise program? Small studies have shown exercise helps with response, but who would be prepared to fund major trials equivalent to a phase 3 trial to definitively prove and quantify the benefits of exercise as an adjunct cancer intervention?
this is a real bugbear for me: a lot of cancers probably have a big life-style contribution, yet there is no easy money to fund proper life-style treatment interventions.
if I wanted to float a biotech company on the ASX to test the benefits of a ketogenic diet and exercise as an adjunct to conventional cancer treatment, would anyone invest in my IPO?
course not! That would be stupid!
- Forums
- ASX - By Stock
- RAC
- Pillar 1 - FTO (new thread)
Pillar 1 - FTO (new thread), page-47
-
- There are more pages in this discussion • 2,975 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RAC (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.69 |
Change
0.000(0.00%) |
Mkt cap ! $288.0M |
Open | High | Low | Value | Volume |
$1.66 | $1.69 | $1.57 | $387.6K | 237.1K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 807 | $1.63 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.69 | 2376 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 807 | 1.630 |
1 | 4000 | 1.600 |
2 | 2300 | 1.580 |
1 | 636 | 1.570 |
1 | 6000 | 1.560 |
Price($) | Vol. | No. |
---|---|---|
1.690 | 2376 | 1 |
1.735 | 3313 | 1 |
1.750 | 2000 | 1 |
1.790 | 1000 | 1 |
1.800 | 2000 | 1 |
Last trade - 16.10pm 04/10/2024 (20 minute delay) ? |
Featured News
LU7
Discover the strong preliminary feasibility of the Bécancour Lithium Refinery, showcasing resilience in a low pricing environment and a strategic plan to capitalize on future price recoveries
RAC (ASX) Chart |